- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
Xarzio currently has the majority of the market share for filgrastim products, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Xarzio currently has the majority of the market share for filgrastim products, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Transcript
While many approved biosimilars have just recently hit the market, Zarxio has been on the market for a few years. What has uptake of this biosimilar been like, and have cost savings been demonstrated?
Uptake has been fairly well. We would consider Zarxio one of the more successful biosimilars available on the market. Just recently, it’s actually become one of the products that has the majority of the market share for the filgrastim products. So, specifically, that product has been doing well compared with all the other biosimilars of course that’s out there.
That is an area where we have seen cost savings within health systems and providers with utilizing the product because it is a lower cost agent. Often times, depending on the site of care, that will determine how much savings you can see pretty immediately. With that type of supportive agent, it’s administered often in inpatient setting. So, lower cost agents is what the goal is for the most part. So, we see cost savings in that areas and then of course for those practices that are participating in the OCM [Oncology Care Model], this is a great opportunity too for a cost savings agent.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More
